Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Aura Biosciences, Inc. (AURA) reported that Montanova Capital, LLC and Aaron Cowen each beneficially owned 2,973,971 shares, or 2.9% of the class, while Averill Master Fund, Ltd. reported 2,535,780 shares, or 2.4%. Each reported shared voting and dispositive power over its stated amount, with no sole voting or dispositive power.
The reported amounts include common stock that may be acquired under pre-funded warrants. Those warrants may be exercised only to the extent post-exercise beneficial ownership does not exceed 9.99%; the Fund may change its limit by written notice to a level no higher than 19.99%.
Key Figures
Montanova Capital and Aaron Cowen beneficial ownership:2,973,971 shares eachAverill Master Fund beneficial ownership:2,535,780 sharesMontanova Capital and Aaron Cowen ownership percentage:2.9% each+4 more
7 metrics
Montanova Capital and Aaron Cowen beneficial ownership2,973,971 shares eachEach reported 2.9% of the class.
Averill Master Fund beneficial ownership2,535,780 sharesReported as 2.4% of the class.
Montanova Capital and Aaron Cowen ownership percentage2.9% eachEach reported beneficial ownership of 2,973,971 shares.
Averill Master Fund ownership percentage2.4%Reported beneficial ownership of 2,535,780 shares.
Pre-funded warrant exercise price$0.00001 per shareWarrants have no expiration date.
Beneficial-ownership limit9.99%Maximum ownership after exercise under the applicable warrant limit.
Maximum adjusted beneficial-ownership limit19.99%The Fund may change its limit by written notice; an increase takes effect on the 61st day after notice is delivered.
Key Terms
Pre-Funded Warrants, Maximum Percentage, Rule 13d-3, shared dispositive power
4 terms
Pre-Funded Warrantsfinancial
"exercise of pre-funded warrants with no expiration date"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Maximum Percentageregulatory
"the “Maximum Percentage”"
Rule 13d-3regulatory
"for purposes of Rule 13d-3 under the Exchange Act"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
shared dispositive powertechnical
"Shared Dispositive Power"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AURA shares did the reporting persons beneficially own?
Montanova Capital, LLC and Aaron Cowen each reported beneficial ownership of 2,973,971 AURA shares, or 2.9%, while Averill Master Fund, Ltd. reported 2,535,780 shares, or 2.4%. Each reported shared voting and dispositive power over its stated amount.
What are the terms of Averill Master Fund’s AURA pre-funded warrants?
The pre-funded warrants have no expiration date and an exercise price of $0.00001 per share. Exercise is limited so that the holders, their affiliates and members of any applicable Section 13(d) group do not exceed the applicable beneficial-ownership cap after exercise. An increase to that cap takes effect on the 61st day after notice is delivered.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Aura Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
05153U107
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Montanova Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,973,971.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,973,971.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,973,971.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Averill Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,535,780.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,535,780.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,535,780.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Aaron Cowen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,973,971.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,973,971.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,973,971.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aura Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
80 Guest Street, Boston, MA 02135
Item 2.
(a)
Name of person filing:
Items 6 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by Averill Master Fund, Ltd. (the "Fund"), which may be deemed to be indirectly beneficially owned by Montanova Capital, LLC and Aaron Cowen, as well as Common Stock that may be acquired upon the exercise of pre-funded warrants with no expiration date with an exercise price of $0.00001 per share of Common Stock ("Pre-Funded Warrants"), subject to the limitations on exercise described below.
The Pre-Funded Warrants are only exercisable to the extent that after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the outstanding Common Stock (the "Maximum Percentage"). By written notice to the Issuer, the Fund may from time to time increase or decrease the Maximum Percentage applicable to it to any other percentage not in excess of 19.99%, provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer. As a result of this restriction, the Pre-Funded Warrants are not all presently exercisable and the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock.
Montanova Capital, LLC
Averill Master Fund, Ltd.
Aaron Cowen
(b)
Address or principal business office or, if none, residence:
Montanova Capital, LLC
11 E 26th Street, 16th Floor
New York, New York 10010
United States of America
Averill Master Fund, Ltd.
c/o Maples Corporate Services Limited
P.O. Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands
Aaron Cowen
c/o Montanova Capital, LLC
11 E 26th Street, 16th Floor
New York, New York 10010
United States of America
(c)
Citizenship:
Montanova Capital, LLC - Delaware
Averill Master Fund, Ltd. - Cayman Islands
Aaron Cowen - United States
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP No.:
05153U107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, par value $0.00001 per share.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please see Exhibit B attached hereto.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Montanova Capital, LLC
Signature:
/s/ Andrew Nathanson
Name/Title:
Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:
11/13/2026
Averill Master Fund, Ltd.
Signature:
/s/ Andrew Nathanson
Name/Title:
Andrew Nathanson, Authorized Signatory
Date:
11/13/2026
Aaron Cowen
Signature:
/s/ Aaron Cowen
Name/Title:
Aaron Cowen
Date:
11/13/2026
Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information
Exhibit A - Joint Filing Agreement
Exhibit B - Control Person Identification